March 3, 2026Open Access

High UBE2D1 expression is associated with poor prognosis and immunotherapy resistance in head and neck cancer

Key Points

Poor prognosis is linked to high levels of UBE2D1 expression in head and neck squamous cell carcinoma.
UBE2D1 is frequently overexpressed, correlating with adverse clinical outcomes in the disease.
Results imply that UBE2D1 may serve as a prognostic biomarker for patient management in HNSCC.
Further validation is needed to confirm UBE2D1's role in predicting immunotherapy response.

Abstract

UBE2D1 is frequently overexpressed in HNSCC and is associated with adverse clinical outcomes. Although its association with immunotherapy response requires further validation, UBE2D1 may be a prognostic biomarker in HNSCC.

High UBE2D1 expression is associated with poor prognosis and immunotherapy resistance in head and neck cancer

Key Points

Abstract

Cite This Study